Retrospective analysis of cutaneous immune‐related adverse events following checkpoint inhibitor therapy in melanoma patients reveals increased risk associated with the HLA‐B*51:01 allele
Our analysis revealed that the HLA-B*51:01 allele was associated with a higher risk of cutaneous irAEs after adjusting for ICI regimen (hazard ratio: 1.71 [95% CI, 1.12-2.61], p = .013.) CONCLUSION: This is the largest study to link an HLA allele with ICI-induced cutaneous irAEs. The findings may support the use of HLA typing as an initial screen for developing irAEs, providing a simple, straightforward metric that can be rapidly performed on patients prior to initiation of ICIs. However, further research is needed across different cancer and toxicity types.
Authors
- Sahira Farooq (ORCID: https://orcid.org/0000-0002-0354-0083)
- Shelby L. Kubicki (ORCID: https://orcid.org/0000-0001-8248-8107)
- Jun Zou (ORCID: https://orcid.org/0000-0003-2443-3516)
- Macartney Welborn (ORCID: https://orcid.org/0000-0002-6587-2032)
- Sana Zahiruddin
- Anisha B. Patel
- Mckenzie DiLeo
- Rebeca Martínez
- Kai Cao
- Lauren E. Haydu
- Samantha Oglesby
- Cheuk Hong Leung
- Kristen E. Pauken
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- University of Florida (US)
- Advanced Powder Solutions (United States) (US)
- Mayo Clinic in Florida (US)
- Indiana University School of Medicine
- Cypress College (US)
- Indiana University – Purdue University Indianapolis (US)
- The University of Texas Health Science Center at Houston (US)
Publication Details
- Journal
- Cancer
- Published
- 2026-01-21
- DOI
- https://doi.org/10.1002/cncr.70262
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 24.20
Funders
- National Institutes of Health
- University of Texas MD Anderson Cancer Center
- National Cancer Institute